Tomasz Stompór

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis

Tomasz Stompór, Mieczysław Pasowicz, Władysław Sułowicz et al. · American Journal of Kidney Diseases · 2002 · 164 citations

Medicine, Clinical Sciences, Nephrology +17

The pharmacokinetics of pioglitazone in patients with impaired renal function

Klemens Budde, Hans‐Hellmut Neumayer, Lutz Fritsche et al. · British Journal of Clinical Pharmacology · 2003 · 142 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16